Acute myocardial infarction: clinical application of technetium 99m stannous pyrophosphate infarct scintigraphy.
Acute myocardial infarction is being recognized as a spectrum of clinical subsets. This appreciation has been brought about to a large degree by the development of several new tools that can be applied clinically to aid in evaluation of patients with acute infarction, and in some cases to provide short and long-term prognostic information. In the realm of noninvasive methods, several tests utilizing radiopharmaceuticals and scintillation cameras have emerged and are rapidly becoming reliable diagnostic parameters in patients with coronary disease and infarction. Technetium 99m (stannous) pyrophosphate (TcPYP) scintigraphy, one of the first of these techniques to find clinical use, has been shown to be an accurate indicator of acute transmural myocardial infarction and provides added sensitivity and specificity to the diagnosis. Increased diagnostic accuracy, the dimension of visible localization and the potential for infarct sizing promise physicians better understanding of a patient's clinical presentation and a more rational approach to management.
D000208:Acute Disease; D003326:Coronary Circulation; D004554:Electric Countershock; D006321:Heart / Q000000981:diagnostic imaging*; D006801:Humans; D008722:Methods; D009203:Myocardial Infarction / Q000000981:diagnostic imaging* / Q000473:pathology / Q000503:physiopathology; D009206:Myocardium / Q000378:metabolism / Q000473:pathology; D011877:Radionuclide Imaging; D012106:Research; D013667:Technetium / Q000378:metabolism; D014003:Tin Polyphosphates / Q000378:metabolism
D014003:Tin Polyphosphates; D013667:Technetium